Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2131-2140 Newer>

Pharmaceutical Executive June 1, 2005 Bill Tancer	Alternative Media: Shared Appeal How do pharma sponsors know if sports' Web sites lure the right visitors to their domains? And how can they tell if a sponsorship deal is connecting their messages with the target market?
Pharmaceutical Executive June 1, 2005 Patrick Burns	Sales Management: A Sample Plan One of the pharma industry's most important promotional tools is also one of its least understood. Here are new approaches to measuring the impact of sampling--and giving reps the tools they need to use samples better.
Pharmaceutical Executive June 1, 2005 Seth Berkley	Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer.
Pharmaceutical Executive June 1, 2005 Jill Wechsler	Washington Report: "D" Is for Data It is critical for Medicare to address important questions on drug safety and utilization, and about how prescribing decisions affect health outcomes and costs.
Pharmaceutical Executive June 1, 2005 Patrick Clinton	Risk: The Series With imported drugs, there's no process, thus no way to guarantee their safety and value. If the supply chain is damaged, the product is suspect. A similar issue is affecting another of pharma's products--the scientific knowledge that informs physicians' decisions and gives them a reason to prescribe.
Pharmaceutical Executive June 1, 2005 Joanna Breitstein	Turn the Page Changes in ethics and expectations are driving the way pharma interacts with medical publishers.
The Motley Fool June 27, 2005 Brian Gorman	Alkermes' Powerful Partnership Alkermes recently agreed to partner with Cephalon to commercialize Alkermes' Vivitrex, an experimental drug to treat alcoholism. The deal should bring strong sales and valuable experience.
The Motley Fool June 27, 2005 Brian Gorman	Pfizer's Controversial Pairing The pharmaceutical's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire. Investors, take note.
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
The Motley Fool June 24, 2005 Nathan Parmelee	What's Next for Healthcare Realty? Healthcare Realty recently dumped its auditor and filed unaudited results. Investors would be wise to wait for the fully audited financial statements.
<Older 2131-2140 Newer> Return to current articles.